ReviewNeuropsychiatric disease and treatment2019
Cognitive impairment in depression: recent advances and novel treatments.
Review in Neuropsychiatric disease and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 172 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing the Efficacy of Metacognitive Training on Depressive Symptoms, Dysfunctional Attitudes and Metacognition in Older Adults Diagnosed With Depression
Neuroimaging Markers of Midlife Depression and Cognitive Behavioural Therapy (CBT)
Who cites it
172 citing papers in PubMed, 8 syntheses or guidelines pooled it, 354 citations in OpenAlex.
- Predicting Response to Pro-Cognitive Interventions in Mood Disorders: A Systematic Review by the International Society for Bipolar Disorders Targeting Cognition Task Force.Acta psychiatrica Scandinavica · 2026Pooled it
- Homocysteine and cognitive function in depression: a systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
- The Effects of Virtual Reality-Based Reminiscence Therapies for Older Adults With Cognitive Impairment: Systematic Review.Journal of medical Internet research · 2024Pooled it
- The Association Between Emotion Recognition and Internalizing Problems in Children and Adolescents: A Three-Level Meta-Analysis.Journal of youth and adolescence · 2024Pooled it
- A meta-analysis investigating the outcomes and correlation between heart rate variability biofeedback training on depressive symptoms and heart rate variability outcomes versus standard treatment in comorbid adult populations.Acta bio-medica : Atenei Parmensis · 2023Pooled it
- Pooled it
- Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: A systematic review and network meta-analysis.Frontiers in aging neuroscience · 2023Pooled it
- Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.The international journal of neuropsychopharmacology · 2022Pooled it
- Effectiveness of cognitive remediation in subjects with major depressive disorder: A multicenter randomized controlled study in a real-world setting.European psychiatry : the journal of the Association of European Psychiatrists · 2025Trial
- A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Tai chi improves psychoemotional state, cognition, and motor learning in older adults during the COVID-19 pandemic.Experimental gerontology · 2021Trial
- Associations between immuno-metabolic markers, working memory, and functional brain activation in depressive and anxiety disorders.Brain, behavior, & immunity - health · 2026Article
- Depressive symptoms and emotion regulation processes: Strategy selection and effectiveness.Emotion (Washington, D.C.) · 2026Article
- Adverse policing as a social exposome pathway: Implications for depression, cognition, and dementia risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Early life stress induces sex-specific changes in cognitive and affective behavior associated with disrupted noradrenergic physiology.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Functional connectivity correlates of reaction time variability in treatment-resistant major depression.Psychological medicine · 2026Article
- Childhood maltreatment and mid-life cognitive functioning: divergent psychosocial pathways linked to ethnoracial group.Journal of behavioral medicine · 2026Article
- Orexinergic Dysregulation in Major Depressive Disorder: Insights from a Prospective Cohort Study Evaluating MADRS, PSQI, and MoCA Scores.Indian journal of psychological medicine · 2026Article
- Personalized machine learning guided intervention for optimizing lifestyle behaviors in depression: a pilot study.NPP - digital psychiatry and neuroscience · 2026Article
- Effectiveness and Tolerability of Vortioxetine in Major Depressive Disorder: A Real-World Study in Switzerland.Clinical drug investigation · 2026Observational
112 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past, little or no attention was paid to cognitive disorders associated with depression (a condition sometimes termed pseudodementia). However, recent years have seen a growing interest in these changes, not only because of their high frequency in acute-stage depression, but also because they have been found to persist, as residual symptoms (in addition to affective and psychomotor ones), in many patients who respond well to antidepressant treatment. These cognitive symptoms seem to impact significantly not only on patients' functioning and quality of life, but also on the risk of recurrence of depression. Therefore, over the past decade, pharmacological research in this field has focused on the development of new agents able to counteract not only depressive symptoms, but also cognitive and functional ones. In this context, novel antidepressants with multimodal activity have emerged. This review considers the different issues, in terms of disease evolution, raised by the presence of cognitive disorders associated with depression and considers, particularly from the neurologist's perspective, the ways in which the clinical approach to cognitive symptoms, and their interpretation to diagnostic and therapeutic ends, have changed in recent years. Finally, after outlining the pharmacodynamics and pharmacokinetics of the first multimodal antidepressant, vortioxetine, it reports the main results obtained with the drug in depressed patients, also in consideration of the ever-increasing evidence on its different mechanisms of action in animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.